# Aralast alpha1-proteinase Inhibitor Surveillance Study

> **NCT00313144** · PHASE4 · TERMINATED · sponsor: **Baxalta now part of Shire** · enrollment: 127 (actual)

## Conditions studied

- Alpha1-antitrypsin Deficiency

## Interventions

- **DRUG:** ARALAST Alpha1-Proteinase Inhibitor

## Key facts

- **NCT ID:** NCT00313144
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-06-09
- **Primary completion:** 2008-12-01
- **Final completion:** 2009-05-01
- **Target enrollment:** 127 (ACTUAL)
- **Why stopped:** Study terminated early due to Aralast being phased out of the market.
- **Last updated:** 2021-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00313144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00313144, "Aralast alpha1-proteinase Inhibitor Surveillance Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00313144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*